Ratings Hyloris Pharmaceuticals SA

Equities

Market Closed - Euronext Bruxelles Other stock markets 11:37:36 2024-04-26 am EDT			5-day change	1st Jan Change
11.7 ^EUR	-1.27%		-.--%	-8.24%

Mar. 14	Hyloris Pharmaceuticals SA Provides Earnings Guidance for 2024	CI
Mar. 14	Transcript : Hyloris Pharmaceuticals SA, 2023 Earnings Call, Mar 14, 2024

From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

The prospective high growth for the next fiscal years is among the main assets of the company
The company is in a robust financial situation considering its net cash and margin position.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The company has insufficient levels of profitability.
Based on current prices, the company has particularly high valuation levels.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.

	1st Jan change	Capi.	ESG Refinitiv
HYLORIS PHARMACEUTICALS SA	-8.24%	354M	-
ELI LILLY AND COMPANY	+39.82%	731B	C+
NOVO NORDISK A/S	+31.34%	586B	B
JOHNSON & JOHNSON	-7.31%	348B	C+
MERCK & CO., INC.	+14.23%	319B	B-
ABBVIE INC.	+0.86%	273B	C+
ASTRAZENECA PLC	+13.47%	235B	B+
ROCHE HOLDING AG	-6.63%	203B	A+
NOVARTIS AG	+7.49%	202B	B-
AMGEN INC.	+4.51%	159B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality